Employees: 3,400
Size Safilo (SFL.MI) is an Italy Health Care company (Medical Specialties) with a market value of $953M, the 85th largest of 121 Italy companies the cockpit tracks. Shares closed at €2.23 on 18 Nov 2026.
Performance Over six months the shares gained 42.0%, against -12.1% for the median peer and +3.1% for the Italy market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue fell 4.1% over the last twelve months (peer median +10.0%); the operating margin is 9.2% (peer median 9.4%).
Valuation It trades at 15.8× forward earnings against a peer median of 20.9× (3rd cheapest of 16).
Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -3 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.1 points above its cost of capital (10.1% WACC).
Next results Next results expected around 16 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €958M | €983M | €993M | €1.02B | €1.08B |
| Revenue growth | — | -1% | -3% | -5% | — |
| Gross profit | €587M | €570M | €562M | €545M | €563M |
| EBITDA | €124M | €102M | €88.7M | €74.1M | €96.9M |
| Net income | €51.4M | €48.6M | €22.3M | -€24.6M | €54.2M |
| Free cash flow | €119M | €81.3M | €64.6M | €37.2M | -€3.58M |
| Capital expenditure | €11.8M | €10.9M | €48.7M | €13.2M | €15.9M |
| Total debt | n/a | €98.3M | €130M | €158M | €191M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SFL.MI | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +15.9% | -6.1% | 2nd highest of 21 |
| 6-month return | +42.0% | -12.1% | 2nd highest of 21 |
| Distance from 52-week high | -6.8% | -32.1% | 2nd highest of 21 |
| Revenue growth (TTM) | -4.1% | +10.0% | 3rd lowest of 21 |
| Operating margin | 9.2% | 9.4% | 11th highest of 21 |
| Forward P/E | 15.8× | 20.9× | 3rd cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | 1.3% | 7.5% | 3rd least demanding of 14 |
| Growth delivered (Del g) | +4.7% | +12.1% | 3rd lowest of 14 |
| Hurdle (Req g minus delivered) | -3.4 pp | -4.4 pp | 6th most demanding of 14 |
| ROIC minus cost of capital | +3.1 pp | +0.9 pp | 9th highest of 20 |
| EV / EBITDA | 7.0× | 10.3× | 2nd cheapest of 10 |
| Net debt / EBITDA | 0.0× | 0.3× | 4th least indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Safilo SFL.MI | Italy | $953M | +42% | -4% | 9% | 15.8× | 1.3% | +4.7% |
| JINS 3046.T | Japan | $963M | -8% | +14% | 10% | 18.7× | -6.1% | +11.7% |
| Menicon 7780.T | Japan | $944M | +26% | +6% | 9% | 20.9× | n/a | n/a |
| L&C BIO 290650.KS | South Korea | $943M | -37% | +65% | 20% | n/a | 32.6% | +21.0% |
| Mani 7730.T | Japan | $965M | -7% | +10% | 30% | 19.9× | 3.3% | +13.9% |
| INKON Life Technology 300143.SZ | China | $985M | -23% | +22% | 12% | 50.3× | 10.7% | +12.9% |
| Ceribell CBLL | United States | $995M | +42% | +31% | -70% | n/a | n/a | n/a |
| Kuros Biosciences KURN.SW | Switzerland | $907M | -12% | +41% | 6% | 70.5× | n/a | n/a |
| Edan Instruments 300206.SZ | China | $1.00B | -19% | +14% | 17% | 18.0× | 6.9% | -2.9% |
| Artivion AORT | United States | $905M | -18% | +14% | 5% | 383.6× | n/a | n/a |
| Amoy Diagnostics 300685.SZ | China | $1.01B | -15% | +7% | 34% | 19.3× | 4.9% | +10.4% |
| Bioventus BVS | United States | $895M | -3% | +4% | 10% | 13.0× | 7.5% | +12.1% |
| PHC 6523.T | Japan | $1.02B | +34% | +3% | 8% | 7.5× | -4.0% | +3.5% |
| Aidite (Qinhuangdao) Technology 301580.SZ | China | $888M | -12% | +17% | 18% | 26.2× | 19.3% | +23.3% |
| Inno Laser Technology 301021.SZ | China | $1.03B | -33% | +17% | 9% | n/a | 50.8% | +8.6% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.03B | -26% | -11% | -33% | n/a | n/a | n/a |
| Eckert & Ziegler EUZ.DE | Germany | $1.03B | -2% | +4% | 26% | 18.5× | 7.7% | +12.1% |
| Castle Biosciences CSTL | United States | $1.03B | +67% | +10% | -7% | n/a | 57.7% | +40.6% |
| Shenzhen YHLO Biotech 688575.SS | China | $882M | -16% | +3% | 12% | 30.7× | 2.0% | +12.7% |
| Hangzhou Biotest Biotech 688767.SS | China | $878M | -12% | -4% | 3% | 37.0× | n/a | n/a |
| Xiangyu Medical 688626.SS | China | $877M | -38% | 0% | 4% | 56.2× | n/a | n/a |